Active Ingredient(s):Lenvatinib FDA Approved: * February 13, 2015 Pharm Company: *EISAI INC Category:Cancer
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
1 Medical uses
2 Adverse effects
4.1 Mechanism of action
7 Brand names
9 External links
* May have multiple approval dates, manufacturers, or labelers.